MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3850
Released On: 4/7/2016
Views: 4589
Released On: 3/31/2016
Views: 3578
Released On: 3/24/2016
Views: 2917
Released On: 3/17/2016
Views: 2475
Released On: 3/11/2016
Views: 2322
Released On: 3/4/2016
Views: 2614
Released On: 3/3/2016
Views: 2311
Released On: 2/23/2016
Views: 3664
Released On: 2/12/2016
Views: 2668
Released On: 2/10/2016
Views: 2383
Released On: 2/9/2016
Views: 2543
Released On: 1/20/2016
Views: 4324
Released On: 1/14/2016
Views: 4787
Released On: 1/5/2016
Views: 3018
Released On: 12/18/2015
Views: 9350
Released On: 12/9/2015
Views: 2782
Released On: 12/3/2015
Views: 3228